Nuevolution

Nuevolution
About Us
Quotes
Change country

Follow us:
Share:
Subscribe:

About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas

Quotes

We are excited about entering into this broad collaboration with Amgen. The agreement with Amgen represents an important business component for Nuevolution in its ambition to discover and develop new medicines for severe diseases, while also capitalizing on Nuevolution’s powerful drug discovery engine. We are looking forward to an excellent working relationship with Amgen’s dedicated research and development teams.

Alex Haahr Gouliaev, CEO

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Nuevolution presents additional positive animal results in Lupus from its BET selective program

Mon, Jun 19, 2017 08:30 CET

Stockholm, 19 June 2017. Nuevolution AB (publ) (NUE.ST) will participate in the BIO International Convention to be held in San Diego, 19-22 June, and will present new data on the company’s bromodomain BET BD1 selective program. Alex Haahr Gouliaev, CEO and Ton Berkien, CBO, will present new data from an eight-week study in a genetic mouse model of Lupus (Mrl-lpr). At age 12 weeks, these animals develop symptoms of Lupus. Twice daily oral treatment for eight weeks with Nuevolution’s bromodomain BET BD1 selective inhibitor NUE7770, led to a dose-dependent reduction of auto-antibody

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Quotes

Nuevolution presents additional positive animal results in Lupus from its BET selective program